

Date: September 10, 2026
REF No: BTL/DT/26-27/16152

To,

- 1) **National Stock Exchange of India Limited**
Exchange Plaza, Bandra Kurla
Complex, Bandra (East),
Mumbai – 400051.
- 2) **BSE Limited**
Floor 25, P. J. Towers,
Dalal Street, Mumbai,
Mumbai – 400001.
- 3) **Symbiotec Pharmalab Limited**
385/2, Pigdamber, Rau, Mhow,
Indore – 45331, Madhya Pradesh, India

Dear Sir,

Sub: Disclosure pursuant to Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 in relation to encumbrance over equity shares of Symbiotec Pharmalab Limited.

This disclosure is being made by Beacon Trusteeship Limited in relation to the creation of encumbrance over the shares of the Symbiotec Pharmalab Limited (“**Target Company**”). We hereby inform you that a debenture trust deed dated 10 December 2025, as amended by a first master amendment deed dated 18 December 2025 (“**Debenture Trust Deed**”), has been entered into between *inter alias* Satwani Holdings (India) Private Limited (“**SHIPL**”) and Beacon Trusteeship Limited in its capacity as the debenture trustee, in relation to the issuance of certain debentures by SHIPL which have been subscribed to by certain investors[†].

Pursuant to the disclosure required to be made under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, please find attached the disclosure in respect of the encumbrance on the equity shares of Symbiotec Pharmalab Limited in favour of Beacon Trusteeship Limited.

Please take the same on record and disseminate the same.

For Beacon Trusteeship Limited acting in its capacity as the debenture trustee.

Authorised Signatory

Name: Vaishnavy Rastogi

Designation: Senior Associate



†

67,550 equity shares in Symbiotec Pharmalab Limited are held by certain affiliates and group companies of the debenture holders holding the Debentures.

2 The disclosure set out herein are consistent with the disclosure made by Symbiotec Pharmalab Limited in its Red Herring Prospectus dated 18 August 2026 and the transaction documents in relation to the Debentures, the copies of which are available on the website of Symbiotec Pharmalab Limited.

BEACON TRUSTEESHIP LIMITED

Registered Office & Corporate Office : 5W, 5th Floor, The Metropolitan, E-Block, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051

Phone : +91 95554 49955 Email : contact@beacontrustee.co.in

Website : www.beacontrustee.co.in CIN : L74999MH2015PLC271288

Mumbai | Bengaluru | Ahmedabad | Pune | Kolkata | Chandigarh | Shimla (HP) | Patna | Delhi | Jaipur | Chennai | GIFT IFSC | Bhopal | Indore | Kochi | Nagpur | Bhubaneswar | Thiruvananthapuram | Lucknow | Hyderabad

df 238

Part A
Annexure

Disclosures under Regulation 29(1) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A- Details of the Acquisition

1. Name of the Target Company (TC)	Symbiotec Pharmalab Limited		
2.Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Beacon Trusteeship Limited acting in its capacity as the debenture trustee.		
3.Whether the acquirer belongs to Promoter/Promoter group	No		
4.Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited and National Stock Exchange of India Limited		
5. Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
<u>Before the acquisition under consideration, holding of acquirer along with PACs of:</u>			
a) Shares carrying voting rights	-	-	-
b) Shares in the nature of encumbrance (pledge/ / others)	-	-	-
c) Voting rights (VR) otherwise than by equity shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
e) Total (a+b+c+d)	-	-	-
<u>Details of acquisition</u>			
a) Shares carrying voting rights acquired	-	-	-
b) VRs acquired otherwise than by equity shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying category) acquired	-	-	-
d) Shares in nature of encumbrance (pledge /lien/ non-disposal-undertaking /others)	34,93,464*	5.44%*	5.43%*
e) Total (a+b+c+d)	34,93,464*	5.44%*	5.43%*
<u>After the acquisition, holding of acquirer along with PACs of:</u>			



a) Shares carrying voting rights	-	-	-
b) VRs otherwise than by equity shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	-	-	-
d) Shares in nature of encumbrance (pledge/others).	34,93,464*	5.44%*	5.43%*
e) Total (a+b+c+d)	34,93,464*	5.44%*	5.43%*
6. Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/ encumbrance, etc.)	By way of encumbrance over the equity shares of the Target Company (see note 1)		
7. Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	See note 1		
8. Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	See note 1		
9. Equity share capital / total voting capital of the TC before the said acquisition	64,256,112		
10. Equity share capital/ total voting capital of the TC after the said acquisition	64,256,112		
11. Total diluted share/voting capital of the TC after the said acquisition	64,280,682		

*Note 1:-

Satwani Holdings (India) Private Limited (“**SHIPL**”) has pursuant to debenture trust deed dated 10 December 2025 and as amended by a first master amendment deed dated 18 December 2025 (“**Debenture Trust Deed**”), entered into between *inter alios* SHIPL and Beacon Trusteeship Limited in its capacity as the debenture trustee (“**Debenture Trustee**”), has issued non-convertible debentures to certain debenture holders.

Pursuant to the terms of the Debenture Trust Deed, Mr. Anil Satwani and Mrs. Kashish Satwani, have created a charge over 100% of the partnership interest in Satwani Holdings LLP in favour of the Debenture Trustee, in accordance with the terms of a deed of hypothecation dated 10 December 2025 entered into between *inter alios*, SHIPL, Satwani Holdings LLP



and the Debenture Trustee. As on the date of this disclosure Satwani Holdings LLP holds [98,19,885] equity shares of the Target Company, constituting [15.28]% of the share capital of the Target Company (on a fully diluted basis).

Further, one of the terms of the Debenture Trust Deed is that, upon the Promoter Group* not owning or ceasing to own at least 26% (twenty six per cent) of the equity share capital or voting rights in the Target Group (on a fully diluted basis), free from any encumbrance (other than pursuant to the Debenture Trust Deed), the 'Debt' (as defined in the Debenture Trust Deed) in relation to the 'Debentures' (as defined in the Debenture Trust Deed) is required to be repaid.

Pursuant to the terms of Debenture Trust Deed and the pledge agreement dated 10-12-2025 (as amended by a first master amendment deed dated 18-12-2025) entered into between the members of the Promotor Group and the Debenture Trustee, the members of Promoter Group have created pledge over the following shares of Target Company

Name of pledgor	Nos. of pledged shares	Date of creation	% w.r.t. total share/voting capital of the Target Company	% w.r.t. total diluted share/voting capital of the Target Company
Mr. Anil Satwani	4,50,896	08-09-2026	0.70%	0.70%
Mr. Sushil Satwani	3,13,938	09-09-2026	0.49%	0.49%
Mrs. Kashish Satwani	5,00,896	08-09-2026	0.78%	0.78%
Satwani holding LLP	22,27,734	08-09-2026	3.47%	3.47%
Total	34,93,464		5.44%	5.43%

Such security over the partnership interest, the pledge over the equity shares of the target company and the covenant on 'change of control' is in the nature of 'encumbrance' (as defined in the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011) and is required to be disclosed.

Signature of the acquirer:

For **Beacon Trusteeship Limited** acting in its capacity as the debenture trustee



Authorised Signatory

Name: Vaishnavy Rastogi

Designation: Senior Associate




* "Promoter Group" shall mean Mr. Anil Satwani, Mrs. Kashish Satwani, Mr. Sushil Satwani, Satwani Holdings LLP, Krishna Anil Satwani Family Trust, Arjun Anil Satwani Family Trust and Kashish and Anil Satwani Family Trust.

Part-B
Name of the Target Company: Symbiotec Pharmalab Limited

Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Whether the acquirer belongs to Promoter/ Promoter group	PAN of the acquirer and/ or PACs
Beacon Trusteeship Limited	No	

Signature of the acquirer:

 For **Beacon Trusteeship Limited** in its capacity as the debenture trustee


Authorised Signatory
Name: Vaishnavy Rastogi
Designation: Senior Associate
Place: Mumbai
Date: September 10, 2026

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.